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Fluconazole pharmacokinetics, including absolute bioavailability, were determined for one group of controls
(n5 10) and two groups of people with human immunodeficiency virus (HIV) infection (those with CD41 T-cell
counts of less than [n 5 4] or greater than [n 5 9] 200 cells per mm3). Twenty subjects received four doses
of fluconazole; three doses were oral (50, 100, and 400 mg), and one dose was intravenous (either 50, 100, or
400 mg). The other three subjects received one or two doses. The groups were comparable in terms of the
weight, body mass index, and estimated creatinine clearance of the subjects, but the people with HIV infection
were older. Pharmacokinetic parameters indicated linearity in all subjects; the area under the plasma con-
centration-time curve and the maximum concentration increased in proportion to the dose. The fraction of an
oral dose of fluconazole absorbed approximated unity in all three groups of subjects. The mean (6 standard
deviation) plasma clearance of fluconazole was lowest in the group of subjects with low CD41 T-cell counts; the
value for this group was 0.74 6 0.19 liter/h, compared with 0.97 6 0.19 liter/h in the group with HIV infection
and CD41 T-cell counts of greater than 200 cells/mm3 and 1.18 6 0.23 liter/h in the group of control subjects
(P < 0.05). The volume of distribution was lower in those with HIV infection (P 5 0.04, corrected for weight).
The half-life was longest in people with HIV infection and low CD41 T-cell counts (P 5 0.01). This study has
shown that some differences do exist between the pharmacokinetics of fluconazole in people with HIV infection
and those in noninfected controls.
Fluconazole, a bis-triazole drug, is useful for the treatment
and prophylaxis of superficial and systematic fungal infections,
which predominantly affect immunocompromised individuals
(14, 15). Such infections, in particular candidiasis and crypto-
coccal meningitis, are common in people infected with the
human immunodeficiency virus (HIV), especially as immune
function deteriorates (17). Specific pharmacokinetic properties
contribute to the therapeutic utility of fluconazole (9). For
example, a low level of protein binding allows high concentra-
tions of drug to cross the blood-brain barrier, making it useful
for the treatment of central nervous system infections, and a
long half-life enables administration only once or twice daily.
Despite widespread use of fluconazole in the treatment and
prophylaxis of these fungal infections in people with HIV in-
fection, dosage regimens have been designed on the basis of
pharmacokinetic data derived from studies with healthy sub-
jects (9). There are a number of reasons for examining the
pharmacokinetics of fluconazole in people with HIV infection,
a group likely to receive the drug therapeutically, to determine
whether individualization of the dosage could be used to op-
timize therapy.
There have been suggestions that the pharmacokinetics of
ketoconazole, another imidazole antifungal drug, may be dose
dependent (8). Recently, similar suggestions have been made
about the pharmacokinetics of another imidazole, itraconazole
(2). Nonlinear pharmacokinetics make accurate dosage predic-
tion difficult, since concentrations in plasma increase dispro-
portionately with dose.
Since HIV infection can affect the physiology of many organ
systems (4, 12), changes in drug disposition in this group could
occur, indicating a need for revision of dosage regimens. To
date, changes in the disposition of some substances, including
folic acid (16) and clindamycin (13), have been reported. It has
been reported that the absorption of ketoconazole is decreased
in the presence of a high gastrointestinal pH (3, 8, 20), a
condition which can occur in people with HIV infection be-
cause of achlorhydria, although this does not appear to occur
with fluconazole (3).
One paper described the bioavailability (of a tablet formu-
lation) and pharmacokinetics of fluconazole in people with
AIDS (11). Single 100-mg intravenous and oral doses of flu-
conazole were administered. Pharmacokinetic parameters
were compared and were found to be similar to those obtained
from population data from previous studies with healthy sub-
jects (historical controls). A concurrent control group was not
included. Data from another recent pharmacokinetic study
indicated that fluconazole clearance was lower in AIDS pa-
tients than in healthy volunteers following administration of
single 100-mg intravenous dose of fluconazole (22). A compre-
hensive study, involving administration of intravenous and oral
doses of different sizes to people with HIV infection and to
concurrent control subjects, was warranted to address unre-
solved issues about the disposition of fluconazole in an iden-
tifiable group of people likely to receive the drug as therapy.
The aims of this study were therefore to (i) investigate the
pharmacokinetics of fluconazole in people with HIV infection
at different doses to determine any nonlinearities in the dis-
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position of the drug, (ii) determine the absolute bioavailability
of three different doses of fluconazole in people with HIV
infection, (iii) evaluate any changes in the pharmacokinetic
parameters of fluconazole with different stages of HIV infec-
tion, and (iv) compare these parameters with those obtained
for a concurrent control group without HIV infection.
MATERIALS AND METHODS
Subjects and study design. The pharmacokinetic parameters of fluconazole,
including the absolute bioavailability of the commercially available capsule for-
mulation (Diflucan; Pfizer Pty Ltd), were determined for three different subject
groups. Group A consisted of volunteers with HIV infection and a CD41 T-cell
count of less than 200 cells per mm3. Group B consisted of volunteers with HIV
infection and a CD41 T-cell count of greater than 200 cells per mm3. Group C
consisted of volunteers without HIV infection.
The CD41 T-cell count was chosen as a marker of disease progression to
differentiate two groups at different stages of HIV infection. It is generally
thought that those with CD41 T-cell counts of lower than 200 cells per mm3 are
at higher risk of opportunistic infection. This surrogate marker of disease pro-
gression is commonly used in therapeutics (e.g., for decisions about commence-
ment of or changes to antiretrovirus therapy).
Inclusion in the study was restricted to males between the ages of 18 and 50
years with a body mass index {weight [kilograms]/(height [meters])2} within the
range of 18 to 26 (1). Subjects were judged to be fit for participation on the basis
of a normal physical examination and clinical chemistry test results, including
liver function tests (acceptable if less than twice the normal ranges, i.e., ,60 IU
of gamma glutamyltransferase and alanine aminotransferase), full blood count
(acceptable if all hematological parameters were within the normal quoted hos-
pital ranges), and serum creatinine (acceptable if creatinine clearance, estimated
from serum creatinine concentration by the formula of Cockcroft and Gault
formula [7], was greater than 3 liters/h). Liver function tests were repeated at the
conclusion of the study. Volunteers in group C had an HIV screen, with full
counseling, to ensure that they had not been exposed to the virus. CD41 T-cell
counts were determined for all subjects in groups A and B before the study was
begun.
The study protocol was approved by the Research Ethics Committee of St.
Vincent’s Hospital, Darlinghurst, Australia. Written informed consent was ob-
tained from each subject prior to participation.
Each subject was scheduled to receive four separate doses of fluconazole
(Diflucan); three doses were oral (one 50-mg capsule, one 100-mg capsule, and
four 100-mg capsules), and one dose was intravenous. The size of the intravenous
dose (either 50, 100, or 400 mg) that a subject received was randomly allocated
within each group by using a random number generator on a calculator. The
order of dosing (intravenous or oral) and the order of the oral doses were
similarly randomly allocated. These random dosing sequences were drawn up for
each group before the study commenced, and subjects were sequentially assigned
a number (e.g., A1 and A2, etc.) upon entry into the study.
The intravenous doses were administered at a constant infusion rate of 200
mg/h (i.e., over 0.25, 0.5, or 2 h, depending upon the dose). The infusion bottle(s)
and all equipment used for administration were weighed before and after dose
administration to calculate the exact dose given. The time between each dose was
at least 2 weeks to ensure an adequate washout period.
All subjects fasted (no food or fluid) from 2200 on the day prior to drug
administration. An indwelling venous cannula was sited on the day of drug
administration (in the arm opposite to that used for the infusion when the subject
was to receive fluconazole intravenously). One venous blood sample was taken
prior to dosing (to ensure that no drug or interfering substance was present
initially), and then 5-ml samples were collected at approximately 0.25, 0.5, 0.75,
1, 1.5, 2, 3, 4, 6, 8, and 10 h after oral dosing, or after commencement of the
infusion, from the indwelling cannula. Blood samples (5 ml) were subsequently
collected by individual venipuncture at 24, 32, 48, 72, 96, 120, and 168 h after
dosing. All samples were collected into vacuum tubes containing EDTA, without
a gel separator layer (Vacutainer; Becton Dickinson, Sydney, Australia), and
centrifuged for 10 min prior to harvest of the plasma. The plasma samples
remained frozen at 2208C until the time of analysis.
The collection of urine was optional. Those volunteers agreeing to participate
in this part of the study were asked to empty the bladder immediately prior to
drug administration. An aliquot of this sample was collected to ensure that no
drug or interfering substance was present initially. Individual void collections
were made during the first 10 h after dose administration, with 24-h collections
carried out for the remainder of the week. The sample volumes and voiding times
were accurately recorded.
Determination of fluconazole concentration. Concentrations of fluconazole in
plasma and urine samples were determined by using a gas-liquid chromato-
graphic method (10), with the following modifications. The internal standard
used was another triazole, UK 48134 (Pfizer Central Research, Sandwich, United
Kingdom), and the gas-liquid chromatograph used was a model 3400 from
Varian Instruments (Frenchs Forest, New South Wales, Australia). The column
was DB-5 (15 m by 0.53 mm [internal diameter] by 1.5 mm) (J&W Scientific,
Folsom, Calif.). The oven temperature was 2008C, the injector temperature was
2608C, and the detector temperature was 2858C. The makeup gas flow rate was
175 ml/min, with a linear carrier gas (nitrogen) velocity of 45 cm/s. The volume
of sample injected was 3.0 ml, and the split injection mode was used, with a split
ratio of 20:1.
To 500-ml samples of plasma, in screw cap glass tubes, were added 500 ml of
carbonate buffer (pH 9.0), the internal standard, and 2.0 ml of chloroform. The
mixture was shaken for 10 min and then centrifuged for 10 min at 3,000 rpm
(Clements GS 200 centrifuge). The upper phase (inorganic) was removed and
discarded, and the remaining organic phase was transferred to a glass centrifuge
tube and evaporated to dryness at a temperature of 388C. Samples were resus-
pended by addition of a drop of chloroform followed by 200 ml of methanol and
then vortexed before being transferred to autosampler vials for injection. The
retention times of fluconazole and the internal standard were 2.4 and 4.3 min,
respectively.
The recovery of fluconazole by use of this modified method was 89, 89, and
91% at concentrations of 0.5, 2, and 10 mg/liter, respectively. The recovery of the
internal standard was 88%. The limit of quantitation of the assay was 0.1 mg/liter.
Within-run coefficients of variation were less than 6% at plasma drug concen-
trations of between 0.5 and 10 mg/liter (n 5 3 at each of four concentrations).
Two standard curves were used for fluconazole concentrations of 0.2 to 2 mg/liter
and 2 to 20 mg/liter; the amounts of internal standard added were 0.8 and 8 mg,
respectively. Concentrations of fluconazole in the study samples were calculated
from the peak area ratios (fluconazole to internal standard) and interpolation
from a freshly extracted standard curve.
The following criteria were used to determine whether an assay run was
accepted: a coefficient of determination (r2) of greater than 0.98 and two of three
quality control samples (concentrations of 0.8 or 8 mg/liter, depending on the
standard curve) within610% of the nominal value. For a concentration result to
be accepted, the coefficient of variation of two duplicate extractions had to be
less than 10%. Samples were reassayed if any criteria were not satisfied.
Pharmacokinetic analysis. Nonlinear least-squares analyses were used to fit
single-exponential elimination equations to the plasma concentration-time data
(each point weighted with the reciprocal of concentration squared) by using
Minim (version 2.0) on a Macintosh computer. A single-exponential elimination
equation was chosen in preference to a biexponential elimination equation on
the basis of Akaike’s information criteria (21). The information criteria were
lower for the single-exponential fits, indicating that nothing was added to the
model by inclusion of further exponentials. Most previous studies have used
single-exponential equations to describe elimination (for a review, see reference
9). One group has used biexponential equations (11), but the estimated half-life
from the central compartment of the model was less than 1/4 h (mean intercom-
partmental clearance of 85 liters/h and mean volume of central compartment of
25 liters after intravenous dosing), compared with a terminal elimination half-life
of around 40 h. This rapid phase would be very hard to model.
Following intravenous dosing, the parameters of the equation C 5 A z e2k z t,
where C is the plasma fluconazole concentration measured at time t after the end
of the intravenous infusion and k is the elimination rate constant, were esti-
mated. A first-order input was used with the following single-exponential elim-
ination to describe disposition after oral dosing: C 5 A z e2k z t 2 B z e2ka z t,
where C is the plasma fluconazole concentration measured at time t after the oral
dose, k is the elimination rate constant, and ka is the absorption rate constant.
Estimations of half-life (t1/2) were obtained from the fitted equation t1/2 5 ln 2/k.
Areas under the plasma concentration-time curves (AUCs) and areas under the
first moments of the curves (AUMCs) were obtained from the plasma concen-
tration-time data by using the linear trapezoidal rule, with an extrapolation to
time infinity.
Noncompartmental pharmacokinetic parameters of fluconazole were charac-
terized. The absolute clearance (CL) of fluconazole after an intravenous dose
(Div) was calculated from the equation CL 5 Div/AUCiv. The volume of distri-
bution at steady state (Vss) was estimated from the equation Vss 5 Div z AUMCiv/
AUCiv2. The renal clearance (CLR) was calculated from the equation CLR 5
CUR z VUR/d z Cmdpt, where CUR is the fluconazole concentration in urine, VUR
is the volume of urine collected over the time interval d, and Cmdpt is the plasma
fluconazole concentration at the time closest to the midpoint of the urine col-
lection interval.
The maximum concentration after oral dosing and the time to achieve this
concentration were obtained from inspection of the plasma concentration-time
data.
The fraction of an oral dose of fluconazole absorbed (F) was calculated from
the equation F 5 Div z AUCor/Dor z AUCiv, where Div and Dor are the doses and
AUCiv and AUCor are the AUCs following intravenous and oral dosing, respec-
tively. This fraction was calculated for each subject from the data obtained after
administration of the equivalent oral and intravenous doses.
Statistical analysis. Data are expressed as mean 6 standard deviation, except
for discontinuous data (time to maximum concentration), for which median
values (and range) are shown. Analysis of variance was used to compare the
demographics of the groups. The linearity of the pharmacokinetics of fluconazole
was assessed by linear regression of the AUC against dose. The correlation of
maximum concentration after oral dosing and dose was determined. The half-
lives at different doses in each of the three groups of subjects were also compared
by using analysis of variance. Bioavailability parameters (fraction of an oral dose
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absorbed, maximum concentration, and time to maximum concentration) were
compared by analysis of variance for the three groups of subjects and at the three
different doses to investigate any differences in absorption either with HIV
infection at different stages or with fluconazole dose. The null hypothesis that
there is no difference in the pharmacokinetics of fluconazole in people with HIV
at two different stages of infection and in noninfected individuals was tested by
comparing total clearance, renal clearance, volume of distribution, and half-life
estimates between the three groups by using analysis of variance.
Correlation coefficients were determined by linear regression analyses, except
for the correlation between maximum concentration and dose, which was deter-
mined by using Spearman’s rank order correlation. One-factor analyses of vari-
ance were performed with the Statview package on a Macintosh computer.
Comparisons of pairs of groups were performed by using unpaired Student’s t
tests. Differences were considered statistically significant if P was , 0.05.
RESULTS
The demographics of the subjects in the three groups are
shown in Table 1. Weight, body mass index, and creatinine
clearance were similar for all three groups (P . 0.05). Subjects
in the two groups with HIV infection were significantly older
than those without infection (P , 0.05 for group A versus
group C and for group B versus group C), but there were no
significant differences in the mean ages of the subjects within
these two groups (P . 0.05 for group A versus group B). Most
subjects in groups A and B were taking a range of other
medications, which are also shown in Table 1.
Investigation of nonlinearities in fluconazole pharmacoki-
netics. There was no evidence of nonlinearities in the disposi-
tion of fluconazole in any subject group. The AUCs following
intravenous doses of fluconazole increased in proportion to
dose in all three groups of subjects (r 5 0.931; P 5 0.0001).
Indeed, the AUCs following all doses, oral and intravenous,
increased in proportion to dose (Fig. 1) (r 5 0.926; P 5
0.0001). The maximum concentrations after oral dosing also
increased proportionally with dose (Fig. 2) (r 5 0.958, P 5
0.0001). There were no trends in any subject for the elimina-
tion half-life of fluconazole to change with dose.
Absorption of oral fluconazole. There were no significant
differences in bioavailability parameters between the groups.
The mean fraction of an oral dose absorbed was essentially 1
(1.1, 1.0, and 0.98 in groups A, B, and C, respectively) (Table
2). The maximum fluconazole concentrations achieved after
oral dosing were similar in all three groups (Fig. 2), and the
time to achievement of these peak concentrations did not differ
between the groups (median [range], 1.3 h [0.5 to 7.0 h], 1.1 h
[0.5 to 3.9 h], and 1.3 h [0.5 to 8.2 h] for groups A, B, and C,
respectively).
Other pharmacokinetic parameters. The total plasma clear-
ance of fluconazole (absolute clearance, calculated from the
intravenous doses) was significantly lower in the group of sub-
TABLE 1. Demographics of subjectsa
Groupb and
subject Age (yr) Wt (kg)
Body surface
area
(kg/m2)
Creatinine
clearance
(liters/h)
Other medication(s)c CD4
1 T-cell count
(cells/mm3)
Group A
A1 37 72 23 6.3 ddI, CO-TRI, Flucloxacillin, Diclofenac 108
A2 25 76 22 8.0 Diazepam 96
A3 34 77 24 6.1 CO-TRI 12
A4 50 61 20 4.8 ZDV, ACYC, CO-TRI 156
Mean (6SD) 37 (610)* 72 (67)† 22 (62)** 6.3 (61.3)††
Group B
B1 35 61 20 8.3 504
B2 50 80 25 5.3 325
B3 35 77 24 6.6 ZDV, CO-TRI, interferon 290
B4 31 65 21 7.3 ZDV 290
B5 46 70 23 5.5 ZDV, ddC 384
B6 29 68 19 5.9 ZDV, CO-TRI, ACYC 224
B7 46 61 20 5.6 ZDV, ACYC 551
B8 38 77 23 5.7 ZDV, ddC, ACYC, NITRAZ, RANIT 418
B9 30 62 20 6.4 ZDV 299
Mean (6SD) 38 (68)* 69 (67)† 22 (62)** 6.3 (61.0)††
Group C
C1 20 85 25 6.1
C2 21 80 24 5.4
C3 21 72 23 8.0
C4 30 73 23 6.7
C5 45 70 23 5.7
C6 21 78 25 7.2
C7 22 88 24 8.4
C8 21 92 26 7.4
C9 22 70 24 5.9
C10 18 62 20 8.2
Mean (6SD) 24 (68)* 77 (69)† 24 (62)** 6.9 (61.1)††
a Analysis of variance: *, P 5 0.0042; †, P 5 0.13; **, P 5 0.07; ††, P 5 0.43.
b Group A, subjects with HIV infection and with CD41 T-cell counts of ,200 cells per mm3; group B, subjects with HIV infection and with CD41 T-cell counts of
.200 cells per mm3; group C, subjects without HIV infection.
c ddI, didanosine; CO-TRI, co-trimoxazole; ZDV, zidovudine; ACYC, acyclovir; ddC, dideoxycytidine; NITRAZ, nitrazepam; RANIT, ranitidine.
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jects with CD1 T-cell counts of less than 200 cells per mm3
(Table 2). Figure 3 shows the fluconazole clearance in each
group (P . 0.05 for group A versus group B; P , 0.05 for
group A versus group C and for group B versus group C).
In the two groups of subjects with HIV infection, there was
no correlation between CD41 T-cell counts and estimated
creatinine clearance (r5 0.026; P5 0.941) or between age and
fluconazole clearance (r 5 0.124; P 5 0.717). For all three
groups of subjects together, i.e., those with HIV infection and
the controls, there was a significant correlation between age
and fluconazole clearance (r 5 0.58; P 5 0.006) but no corre-
lation between fluconazole clearance and estimated creatinine
clearance (r 5 0.226; P 5 0.324).
The volume of distribution of fluconazole was lower in the
groups of subjects with HIV infection (Table 2), even when the
results were corrected for weight (P 5 0.04). The group of
subjects with HIV infection and low CD41 T-cell counts had
the longest elimination half-life of fluconazole (Table 2; P .
FIG. 1. AUC versus dose. Exact intravenous (IV) doses were estimated by weight, as described in Materials and Methods.
FIG. 2. Maximum fluconazole concentration after oral dosing (Cmax) versus dose.
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0.05 for group B versus group C, and P , 0.05 for group A
versus group B and group A versus group C).
Only eight subjects collected urine (two each in groups A
[subjects A1 and A2] and B [subjects B2 and B3] and four in
group C [subjects C2, C3, C4, and C5]), and only two of these
(C4 and C5) provided complete collections for all doses. The
other urine collections were sparse, often only over the first 8
to 10 h after one or more doses. The mean renal clearance of
fluconazole tended to be lower in those groups with HIV
infection (0.20 [60.08] liter/h and 0.58 [60.02] liter/h for
groups A and B, respectively; 0.79 [60.23] liter/h for group C),
although this difference was statistically significant only for the
comparison between the group with the lowest CD41 T-cell
count and the non-HIV-infected control group (P5 0.10) (P,
0.05 for group A versus group C; P . 0.05 for group B versus
group C and for group A versus group B).
DISCUSSION
The pharmacokinetics of fluconazole were linear in both
HIV-infected subjects and controls. Not all subjects received
four doses as originally planned. One subject (subject A3)
withdrew because of other illnesses, one (subject B9) did not
return after the first dose, and one (subject B8) elected to have
two doses. The data for the completed doses are included in
the analyses.
The bioavailability in all subjects, at all three doses studied,
was rapid and complete. There was an unexplained error in the
AUC after the 50-mg oral dose for subject C2 (Table 2). When
the dose-normalized AUCs for the 100- and 400-mg oral doses
were compared with the dose-normalized AUC after intrave-
nous dosing, absolute bioavailabilities of 1.05 and 1.00, respec-
tively, were obtained.
The null hypothesis of no difference in the pharmacokinetics
of fluconazole in people with HIV at two different stages of
infection and in noninfected individuals can be rejected. The
lower total clearance of fluconazole in volunteers with HIV
infection and a low CD41 T-cell count (,200 cells per mm3)
than in the other volunteers with HIV infection and in the
non-HIV-infected subjects, is unlikely to be due to chance (P
, 0.05). The volume of distribution and half-life also differed
between the groups of HIV-infected and control subjects.
There were age differences between the people with HIV
infection and the noninfected controls. Fluconazole clearance
was inversely correlated with age for all of the subjects, al-
though there was no such correlation for just the subjects with
HIV infection. The question is whether age is a true con-
founder (i.e., a de facto measure of CD41 T-cell count) or
whether age per se causes a true difference in fluconazole
clearance. A previous paper has reported no effect on half-life
attributable to age in a group of subjects over 65 years of age
(the mean half-life was reported to be 37 h, which is similar to
TABLE 2. Summary of pharmacokinetic parameters of fluconazolea
Groupb and subject t1/2 (h)c Size of i.v. dose (mg) F CL (liters/h) Vss (liters)
Group A
A1 69 400 1.02 0.53 56
A2 32 390 1.24 0.91 45
A3 63
A4 37 53 1.14 0.78 33
Mean (6SD) 50 (618)* 1.13 (60.11)† 0.74 (60.19)** 45 (612)††
Group B
B1 25 95 1.29 1.19 44
B2 42 372 0.95 0.87 47
B3 36 390 1.03 0.87 42
B4 25 46 0.92 1.18 41
B5 26 44 1.19 1.19 46
B6 31 96 0.92 0.85 40
B7 29 94 1.15 0.82 31
B8 42 42 0.84 0.76 41
B9 35
Mean (6SD) 32 (67)* 1.04 (60.16)† 0.97 (60.19)** 42 (65)††
Group C
C1 36 94 0.87 1.38 78
C2 34 55 1.62 1.38 61
C3 33 350 1.03 1.13 49
C4 37 374 0.85 0.98 50
C5 33 49 0.86 0.89 43
C6 38 49 0.98 1.11 60
C7 46 92 0.78 0.93 58
C8 38 94 0.89 1.57 63
C9 36 39 0.97 1.34 78
C10 31 356 0.94 1.11 42
Mean (6SD) 36 (64)* 0.98 (60.24)† 1.18 (60.23)** 58 (613)††
a Abbreviations: t1/2, half-life; i.v., intravenous; F, fraction of oral dose absorbed, CL, clearance; Vss, volume of distribution at steady state. Analysis of variance:
*, P 5 0.01; †, P 5 0.49; **, P 5 0.01; ††, P 5 0.008.
b See Table 1, footnote b.
cMean of results for oral and intravenous doses.
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that for the controls in the present study) (5). The mean age in
group A in the present study was 37 years; the mean age in
group C was 24 years. It is unlikely that this age difference
alone can account for the mean 37% difference in fluconazole
clearance between the groups. The mean ages in groups B and
C were the same, but there was still a 20% difference in flu-
conazole clearance between the groups. It is unlikely that age
alone was responsible for alterations in fluconazole clearance.
Another potential confounding factor is renal function.
However, there was no correlation between estimated creati-
nine clearance and fluconazole clearance in the present study.
Other investigators have reported decreased fluconazole clear-
ance in people with impaired renal function (9); however,
fluconazole clearances of as low as 0.7 liter/h (similar to that
calculated in the present study for group A) have been re-
ported only for groups with creatinine clearances of 2.4 liters/h
(18). This is half of the lowest value estimated in the present
study (4.8 liters/h).
In normal volunteers, renal clearance has been estimated to
account for between 70 and 80% of total fluconazole clearance
(9). It was unfortunate that in the present study more urine
data were not available, as definite conclusions should not be
drawn from the small amount of data collected. It appeared
that renal clearance of fluconazole accounted for a much lower
proportion of total clearance in those with HIV infection and
low CD41 T-cell counts (27%). There were no extra peaks on
the chromatograms indicating potential metabolites. Is is pos-
sible that in the HIV-infected group secretion of fluconazole is
less and/or reabsorption is higher. The Cockcroft-Gault nomo-
gram may be inaccurate as a measure of glomerular filtration
rate for people with HIV infection. This is worth further in-
vestigation, since this is a common nomogram used to deter-
mine the dosage of renally eliminated drugs. Specific effects of
the viral infection upon drug disposition processes do not ap-
pear to have been studied, although renal pathology has been
reported (4).
One previous study found no differences in fluconazole
pharmacokinetics between people with AIDS and historic con-
trols (11). The clearance values after the intravenous dose, 0.53
to 1.49 liters/h, encompass the values determined in the
present study. The mean fraction of an oral tablet dose ab-
sorbed was 1.0, which is also in agreement with the data for the
capsule reported here.
The findings of another study indicated that fluconazole
clearance after a single 100-mg intravenous dose was lower in
AIDS patients (CD41 T-cell counts, 5 to 99/mm3) than in a
concurrent control group (mean, 1.02 and 1.38 liters/h, respec-
tively; P , 0.05) (22). These estimates are slightly higher than
those obtained in the present study, possibly because of differ-
ent methods of drug and data analysis. Also, the subjects in the
previous study were on average 13% lighter than those in the
present study. One case study of a patient with AIDS reported
a clearance of 0.57 liter/h (6), but this patient had an estimated
creatinine clearance of only 3.7 liters/h.
In the present study, subjects with HIV infection were
screened carefully. None had diarrhea, were emaciated or un-
derweight, or had abnormal liver function tests. The stringent
criteria caused a problem with recruitment (19). Potential re-
cruits for the group with lower CD41 T-cell counts were es-
pecially likely to be ill, to be taking potentially interacting
medications, or to have pathology excluding them from the
study. However, the differences in kinetic parameters were
large, so that even with the small numbers of subjects available,
statistically significant differences were detected.
Subjects with HIV infection were taking a range of other
medications (Table 1), but only subject B8 was taking a poten-
tially interacting drug (ranitidine, which may affect absorption
because of increased gastric pH). However, the bioavailability
data for this subject were similar to those for other subjects.
Another study has demonstrated lower clearance of a drug,
clindamycin, in patients with AIDS (13). Clindamycin is elim-
inated primarily by metabolism, with only 10% excreted un-
changed; therefore, no parallels with the findings of this study
can be drawn.
A study of folic acid disposition in people with HIV infection
suggested that absorption of this compound was impaired (16).
Another possible interpretation of those blood concentration-
time data could be that clearance was altered (increased),
although it is not possible to determine this from the oral data
presented.
FIG. 3. Plasma clearance (absolute) of fluconazole in all subjects from groups A, B, and C.
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In conclusion, the main findings of this study are as follows.
(i) The pharmacokinetics of fluconazole are linear over the
dosing range of 50 to 400 mg for both intravenous and oral
administration. (ii) The absolute bioavailability of the commer-
cially available oral capsule of fluconazole is essentially one in
people with and without HIV infection. (iii) The total plasma
clearance and volume of distribution of fluconazole were lower
in a group of people with HIV infection and low CD41 T-cell
counts than in a group with higher CD41 T-cell counts and in
uninfected subjects.
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